Mean change in UEC total score from the start of the Phase2/3 study (Week 0) to the final evaluation time point (Week 120) of the extension study. Closed circle and solid line, SA-ER/SA-ER group; open ...

If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...

Review clinical classifications, diagnostic procedures, and management strategies for cardiomyopathy and heart failure in this comprehensive overview.

Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, ...

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

The American Heart Association has issued its first scientific treatment statement for pediatric cardiomyopathy, a rare disorder affecting the structure of the heart muscle that can lead to heart ...

BUFFALO, N.Y. – The American Heart Association has issued its first scientific treatment statement for pediatric cardiomyopathy, a rare disorder affecting the structure of the heart muscle that can ...